PI3K inhibitors in advanced breast cancer: alpelisib
Breast cancer is among the most common cancers and a major cause of cancer-related death.1 Although the outlook for patients with early breast cancer is good, advanced breast cancer is still...
These materials have been developed to help healthcare professionals review the evidence supporting the role of alpelisib, a highly selective inhibitor of PI3K-alpha, for the treatment of advanced breast cancer.
Articles
Alpelisib in the treatment of breast cancer: managing adverse events
Advances in management have greatly improved outcomes for women with early breast cancer and drug treatment has replaced surgery as the primary treatment option for many patients.1 Advanced breast...
Alpelisib in the treatment of breast cancer: overall survival and sequencing
PIK3CA mutations are present in approximately 40% of HR+ tumours.1 In clinical trials in women with HR+/HER2– advanced breast cancer, the frequency of PIK3CA mutations was 33–43%.2–4 SOLAR-1, a...
Alpelisib in the treatment of breast cancer: managing hyperglycaemia to support treatment
Alpelisib is an alpha-selective PI3K inhibitor. In combination with fulvestrant, it prolongs progression-free survival in postmenopausal women, and men, with HR+/HER2–, PIK3CA-mutated, advanced or...
